As Gilead Sciences INC (GILD) Valuation Rose, Shareholder Zacks Investment Management Trimmed Its Holding by $4.01 Million

April 26, 2018 - By Louis Casey

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It turned negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Grandfield & Dodd Limited Liability Co reported 1.04% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Valueworks Limited Liability Corporation has invested 3.71% in Gilead Sciences, Inc. (NASDAQ:GILD). Palisade Mgmt Ltd Llc Nj invested 0.02% in Gilead Sciences, Inc. (NASDAQ:GILD). Aimz Advsrs Ltd Liability stated it has 2.06% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Peoples Fin Corporation owns 953 shares or 0.04% of their US portfolio. 57,785 were reported by Jolley Asset Mngmt Ltd Limited Liability Company. Voya Inv Mngmt Lc, a Georgia-based fund reported 3.57M shares. Gw Henssler Associate holds 1.14% or 170,470 shares. Murphy Management has 0.07% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 7,204 shares. 84,581 are owned by Comml Bank Of The West. Nelson Roberts Advisors Ltd Co reported 1.7% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Rothschild Invest Il holds 14,270 shares or 0.11% of its portfolio. Bridges Invest Mngmt has 0.43% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 73,805 shares. Retirement Systems Of Alabama has 1.05 million shares for 0.36% of their portfolio. Richard Bernstein Advsr Llc holds 50 shares.

Since January 2, 2018, it had 0 buys, and 19 insider sales for $40.38 million activity. The insider Cogan John Francis sold $437,588. Washington Robin L had sold 5,000 shares worth $401,566. 50,000 shares were sold by MARTIN JOHN C, worth $3.93 million on Thursday, March 1. Meyers James R had sold 100,000 shares worth $8.02 million on Tuesday, January 16. 60,000 shares were sold by WILSON GAYLE E, worth $4.68M on Friday, February 9.

Zacks Investment Management decreased its stake in Gilead Sciences Inc (GILD) by 9.4% based on its latest 2017Q4 regulatory filing with the SEC. Zacks Investment Management sold 56,503 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 544,382 shares of the health care company at the end of 2017Q4, valued at $39.00M, down from 600,885 at the end of the previous reported quarter. Zacks Investment Management who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $95.51B market cap company. The stock increased 0.73% or $0.53 during the last trading session, reaching $73.25. About 6.34M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 26, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Zacks Investment Management, which manages about $3.45B and $4.59 billion US Long portfolio, upped its stake in Home Depot Inc (NYSE:HD) by 38,600 shares to 572,149 shares, valued at $108.44M in 2017Q4, according to the filing. It also increased its holding in Ameriprise Finl Inc (NYSE:AMP) by 43,594 shares in the quarter, for a total of 415,936 shares, and has risen its stake in American Express Co (NYSE:AXP).

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 earnings per share, down 27.73 % or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07B for 11.52 P/E if the $1.59 EPS becomes a reality. After $1.60 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63 % negative EPS growth.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 15 analysts covering Gilead Sciences (NASDAQ:GILD), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Gilead Sciences has $103.0 highest and $77.0 lowest target. $90.08’s average target is 22.98% above currents $73.25 stock price. Gilead Sciences had 25 analyst reports since October 27, 2017 according to SRatingsIntel. As per Monday, January 29, the company rating was maintained by Wells Fargo. As per Wednesday, January 3, the company rating was maintained by Credit Suisse. The firm earned “Overweight” rating on Tuesday, March 6 by Barclays Capital. The stock has “Buy” rating by Mizuho on Monday, February 5. The stock has “Market Perform” rating by Leerink Swann on Wednesday, February 7. The stock has “Neutral” rating by Credit Suisse on Wednesday, December 20. Mizuho maintained it with “Buy” rating and $83.0 target in Wednesday, November 8 report. Leerink Swann maintained the shares of GILD in report on Thursday, February 22 with “Hold” rating. The firm has “Buy” rating given on Wednesday, February 7 by Cowen & Co. The rating was maintained by BMO Capital Markets on Friday, October 27 with “Outperform”.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.